Literature DB >> 29704038

Quantitative evaluation of tau PET tracers 18F-THK5351 and 18F-AV-1451 in Alzheimer's disease with standardized uptake value peak-alignment (SUVP) normalization.

Jingyun Chen1, Yi Li2, Elizabeth Pirraglia1, Nobuyuki Okamura3, Henry Rusinek1,4, Mony J de Leon1.   

Abstract

PURPOSE: Off-target binding in the reference region is a challenge for recent tau tracers 18F-AV-1451 and 18F-THK5351. The conventional standardized uptake value ratio (SUVR) method relies on the average uptake from an unaffected tissue sample, and therefore is susceptible to biases from off-target binding as well as variability among individuals in the reference region. We propose a new method, standardized uptake value peak-alignment (SUVP), to reduce the bias of the SUVR, and improve the quantitative assessment of tau deposition.
METHODS: The SUVP normalizes uptake values by their mode and standard deviation. Instead of using a reference region, the SUVP derives the contrast from unaffected voxels over the whole brain. Using SUVP and SUVR methods, we evaluated the global and regional tau binding of 18F-THK5351 and 18F-AV-1451 on two independent cohorts (N = 18 and 32, respectively), each with cognitively normal (NL) subjects and Alzheimer's disease (AD) subjects.
RESULTS: Both tracers showed significantly increased binding for AD in the targeted cortical areas. In the temporal cortex, SUVP had a higher classification success rate (CSR) than SUVR (0.96 vs 0.89 for 18F-THK5351; 0.86 vs 0.75 for 18F-AV-1451), as well as higher specificity under fixed sensitivity around 0.80 (0.70 vs 0.45 specificity for 18F-THK5351; 1.00 vs 0.78 for 18F-AV-1451). In the cerebellar cortex, an AD-NL group difference with effect size (Cohen's d) of 0.62 was observed for AV-1451, confirming the limitation of the SUVR approach using this region as a reference. A smaller cerebellar effect size (0.09) was observed for THK5351.
CONCLUSION: The SUVP method reduces the bias of the reference region and improves the NL-AD classification compared to the SUVR approach.

Entities:  

Keywords:  Alzheimer’s disease; PET; Peak-alignment; Standardized uptake value; Tau

Mesh:

Substances:

Year:  2018        PMID: 29704038      PMCID: PMC6174003          DOI: 10.1007/s00259-018-4040-1

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  24 in total

Review 1.  Tau protein as a differential biomarker of tauopathies.

Authors:  Nicolas Sergeant; André Delacourte; Luc Buée
Journal:  Biochim Biophys Acta       Date:  2005-01-03

2.  The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET.

Authors:  William E Klunk; Robert A Koeppe; Julie C Price; Tammie L Benzinger; Michael D Devous; William J Jagust; Keith A Johnson; Chester A Mathis; Davneet Minhas; Michael J Pontecorvo; Christopher C Rowe; Daniel M Skovronsky; Mark A Mintun
Journal:  Alzheimers Dement       Date:  2014-10-28       Impact factor: 21.566

Review 3.  Tauopathies: classification and clinical update on neurodegenerative diseases associated with microtubule-associated protein tau.

Authors:  D R Williams
Journal:  Intern Med J       Date:  2006-10       Impact factor: 2.048

4.  Cortical laminar binding of PET amyloid and tau tracers in Alzheimer disease.

Authors:  Yi Li; Wai Tsui; Henry Rusinek; Tracy Butler; Lisa Mosconi; Elizabeth Pirraglia; David Mozley; Shankar Vallabhajosula; Ryuichi Harada; Shozo Furumoto; Katsutoshi Furukawa; Hiroyuki Arai; Yukitsuka Kudo; Nobuyuki Okamura; Mony J de Leon
Journal:  J Nucl Med       Date:  2015-01-08       Impact factor: 10.057

5.  Distribution of monoamine oxidase proteins in human brain: implications for brain imaging studies.

Authors:  Junchao Tong; Jeffrey H Meyer; Yoshiaki Furukawa; Isabelle Boileau; Li-Jan Chang; Alan A Wilson; Sylvain Houle; Stephen J Kish
Journal:  J Cereb Blood Flow Metab       Date:  2013-02-13       Impact factor: 6.200

6.  18F-THK5351: A Novel PET Radiotracer for Imaging Neurofibrillary Pathology in Alzheimer Disease.

Authors:  Ryuichi Harada; Nobuyuki Okamura; Shozo Furumoto; Katsutoshi Furukawa; Aiko Ishiki; Naoki Tomita; Tetsuro Tago; Kotaro Hiraoka; Shoichi Watanuki; Miho Shidahara; Masayasu Miyake; Yoichi Ishikawa; Rin Matsuda; Akie Inami; Takeo Yoshikawa; Yoshihito Funaki; Ren Iwata; Manabu Tashiro; Kazuhiko Yanai; Hiroyuki Arai; Yukitsuka Kudo
Journal:  J Nucl Med       Date:  2015-11-05       Impact factor: 10.057

7.  Tau positron emission tomographic imaging in aging and early Alzheimer disease.

Authors:  Keith A Johnson; Aaron Schultz; Rebecca A Betensky; J Alex Becker; Jorge Sepulcre; Dorene Rentz; Elizabeth Mormino; Jasmeer Chhatwal; Rebecca Amariglio; Kate Papp; Gad Marshall; Mark Albers; Samantha Mauro; Lesley Pepin; Jonathan Alverio; Kelly Judge; Marlie Philiossaint; Timothy Shoup; Daniel Yokell; Bradford Dickerson; Teresa Gomez-Isla; Bradley Hyman; Neil Vasdev; Reisa Sperling
Journal:  Ann Neurol       Date:  2015-12-15       Impact factor: 10.422

8.  Tau-PET uptake: Regional variation in average SUVR and impact of amyloid deposition.

Authors:  Prashanthi Vemuri; Val J Lowe; David S Knopman; Matthew L Senjem; Bradley J Kemp; Christopher G Schwarz; Scott A Przybelski; Mary M Machulda; Ronald C Petersen; Clifford R Jack
Journal:  Alzheimers Dement (Amst)       Date:  2016-12-21

9.  Considerations and code for partial volume correcting [18F]-AV-1451 tau PET data.

Authors:  Suzanne L Baker; Anne Maass; William J Jagust
Journal:  Data Brief       Date:  2017-10-16

10.  An autoradiographic evaluation of AV-1451 Tau PET in dementia.

Authors:  Val J Lowe; Geoffry Curran; Ping Fang; Amanda M Liesinger; Keith A Josephs; Joseph E Parisi; Kejal Kantarci; Bradley F Boeve; Mukesh K Pandey; Tyler Bruinsma; David S Knopman; David T Jones; Leonard Petrucelli; Casey N Cook; Neill R Graff-Radford; Dennis W Dickson; Ronald C Petersen; Clifford R Jack; Melissa E Murray
Journal:  Acta Neuropathol Commun       Date:  2016-06-13       Impact factor: 7.801

View more
  6 in total

Review 1.  Radioactive synthesis of tau PET imaging agent 18F-AV-1451 and its role in monitoring the progression of Alzheimer's disease and supporting differential diagnosis.

Authors:  Wenyan Zhang; Shuoyan Xu; Hongmei Yu; Xuena Li; Zhuangzhuang Jin; Yaming Li; Zhiyi He
Journal:  Ann Nucl Med       Date:  2021-01-18       Impact factor: 2.668

Review 2.  Overview of tau PET molecular imaging.

Authors:  Gabriel Cassinelli Petersen; Michelle Roytman; Gloria C Chiang; Yi Li; Marc L Gordon; Ana M Franceschi
Journal:  Curr Opin Neurol       Date:  2022-04-01       Impact factor: 6.283

Review 3.  Clinical validity of increased cortical binding of tau ligands of the THK family and PBB3 on PET as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework.

Authors:  Konstantinos Chiotis; Alessandra Dodich; Marina Boccardi; Cristina Festari; Alexander Drzezga; Oskar Hansson; Rik Ossenkoppele; Giovanni Frisoni; Valentina Garibotto; Agneta Nordberg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-03-15       Impact factor: 9.236

4.  GC-CNNnet: Diagnosis of Alzheimer's Disease with PET Images Using Genetic and Convolutional Neural Network.

Authors:  Morteza Amini; Mir Mohsen Pedram; AliReza Moradi; Mahdieh Jamshidi; Mahshad Ouchani
Journal:  Comput Intell Neurosci       Date:  2022-08-09

Review 5.  Applications of amyloid, tau, and neuroinflammation PET imaging to Alzheimer's disease and mild cognitive impairment.

Authors:  Avinash Chandra; Polytimi-Eleni Valkimadi; Gennaro Pagano; Oliver Cousins; George Dervenoulas; Marios Politis
Journal:  Hum Brain Mapp       Date:  2019-09-14       Impact factor: 5.038

Review 6.  Recent Developments in Positron Emission Tomography Tracers for Proteinopathies Imaging in Dementia.

Authors:  Ruiqing Ni; Roger M Nitsch
Journal:  Front Aging Neurosci       Date:  2022-01-03       Impact factor: 5.750

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.